DG Comp official: invisible hand isn’t working in pharma
Pharmaceutical investment incentives are better fueled by longer patent periods than by governments allowing drugmakers to block entry or charge excessive prices, a director at the European Commission’s Directorate-General for Competition has said.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.